Background Anxiety and related disorders are among the most common mental disorders,
with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are …

PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH OBSESSIVE-COMPULSIVE
DISORDER Page 1 Not for Distribution or Citation Draft 2, December 6, 2005 PRACTICE …

Anxiety disorders, as a group, are among the most common mental health conditions and
frequently cause significant functional impairment. Both psychotherapeutic and …

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002,
World J Biol Psychiatry 3: 171), recommendations for the pharmacological treatment of …

Serotonin reuptake inhibitor (SRI) medications are well established as first-line
pharmacotherapeutic treatment for Obsessive-Compulsive Disorder (OCD). However …

In addition to the open-mindedness of the authors, the surprising content of these
hypotheses illustrates how dramatically the attitude towards OCS has shifted in a few …

The evidence for the involvement of the serotonergic system in the pathogenesis of
obsessive-compulsive disorder (OCD) is circumstantial at best, despite being the focus for …

Obsessive-compulsive disorder (OCD) is a common psychiatric disorder that produces
significant morbidity. The introduction of serotonin reuptake inhibitors in the 1980s …

Summary Abstract Mirtazapine (Remeron®, Zispin®) is a noradrenergic and specific
serotonergic antidepressant (NaSSA) that is approved in many counties for use in the …

Knowledge of pharmacotherapeutic treatment options in obsessive-compulsive disorder
(OCD) has grown considerably over the past 40 years. Serotonergic antidepressants, such …